Literature DB >> 24508505

High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease.

Sophie Stukas1, Jérôme Robert1, Cheryl L Wellington2.   

Abstract

Cerebrovascular dysfunction significantly contributes to the clinical presentation and pathoetiology of Alzheimer's disease (AD). Deposition and aggregation of β-amyloid (Aβ) within vascular smooth muscle cells leads to inflammation, oxidative stress, impaired vasorelaxation, and disruption of blood-brain barrier integrity. Midlife vascular risk factors, such as hypertension, cardiovascular disease, diabetes, and dyslipidemia, increase the relative risk for AD. These comorbidities are all characterized by low and/or dysfunctional high-density lipoproteins (HDL), which itself is a risk factor for AD. HDL performs a wide variety of critical functions in the periphery and CNS. In addition to lipid transport, HDL regulates vascular health via mediating vasorelaxation, inflammation, and oxidative stress and promotes endothelial cell survival and integrity. Here, we summarize clinical and preclinical data examining the involvement of HDL, originating from the circulation and from within the CNS, on AD and hypothesize potential synergistic actions between the two lipoprotein pools.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24508505     DOI: 10.1016/j.cmet.2014.01.003

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  37 in total

1.  Transcriptome Sequencing Identifies Potential Biomarker for White Matter Lesions Diagnosis in the Hypertension Population.

Authors:  Wendi Wang; Pei Sun; Fengyue Han; Chunjuan Wang; Yongxiang Wang; Xiang Wang; Lin Cong; Chuanqiang Qu
Journal:  Neurochem Res       Date:  2021-05-26       Impact factor: 3.996

2.  LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice.

Authors:  Sophie Stukas; Lita Freeman; Michael Lee; Anna Wilkinson; Alice Ossoli; Boris Vaisman; Stephen Demosky; Jeniffer Chan; Veronica Hirsch-Reinshagen; Alan T Remaley; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2014-06-20       Impact factor: 5.922

3.  Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis.

Authors:  Andrew L Zhou; Suresh K Swaminathan; Geoffry L Curran; Joseph F Poduslo; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

4.  Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance.

Authors:  Yohei Shibuya; Catherine C Y Chang; Li-Hao Huang; Elena Y Bryleva; Ta-Yuan Chang
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

Review 5.  Cellular cholesterol homeostasis and Alzheimer's disease.

Authors:  Ta-Yuan Chang; Yoshio Yamauchi; Mazahir T Hasan; Catherine Chang
Journal:  J Lipid Res       Date:  2017-03-15       Impact factor: 5.922

Review 6.  HDL and cognition in neurodegenerative disorders.

Authors:  David A Hottman; Dustin Chernick; Shaowu Cheng; Zhe Wang; Ling Li
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

7.  Alzheimer's Disease Genetics and ABCA7 Splicing.

Authors:  Jared B Vasquez; James F Simpson; Ryan Harpole; Steven Estus
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Genetic markers of cholesterol transport and gray matter diffusion: a preliminary study of the CETP I405V polymorphism.

Authors:  Lauren E Salminen; Peter R Schofield; Kerrie D Pierce; Xi Luo; Yi Zhao; David H Laidlaw; Ryan P Cabeen; Thomas E Conturo; Elizabeth M Lane; Jodi M Heaps; Jacob D Bolzenius; Laurie M Baker; Sarah A Cooley; Staci Scott; Lee M Cagle; Robert H Paul
Journal:  J Neural Transm (Vienna)       Date:  2015-08-08       Impact factor: 3.575

Review 9.  Vasculoprotection as a Convergent, Multi-Targeted Mechanism of Anti-AD Therapeutics and Interventions.

Authors:  Narayan R Bhat
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.

Authors:  Cutler T Lewandowski; Juan Maldonado Weng; Mary Jo LaDu
Journal:  Neurobiol Dis       Date:  2020-02-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.